StockData

Ascentage Pharma Group International vs Legend Biotech

AAPG and LEGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AAPG and LEGN compare

Legend Biotech grew revenue faster over the last twelve months (59.5% versus −41.5% for Ascentage Pharma Group International).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAAPGLEGN
Size and price
Share price$13.14$16.11
Change, 1 year−61.7%−46.8%
Change, 5 years–−70.2%
Beta (5Y)1.430.80
Employees7672,900
StockData Score
Total score33
Valuation score00
Growth score12 (better)
Performance score1 (better)0
Health score11
Dividend score00
Growth
Revenue growth (TTM)−41.5%59.5% (better)
Revenue growth, 5Y average–68.8%
Profitability
Gross margin91.5% (better)57.2%
Operating margin–−4.3%
Net margin−216%–
FCF margin−209%−9.6% (better)
Return on equity−156%–
Financial health
Debt / equity1.50–
Interest coverage–−2.5×
Current ratio1.793.04 (better)
Ownership
Held by institutions0.00%28.4%
Held by insiders13.0%0.50%
Insider net buying, 12 months–−$384K
Superinvestors holding–1

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.